383P An exosome-based liquid biopsy assay for predicting therapeutic outcomes in patients with metastatic colorectal cancer treated with anti-EGFR therapy: Results from prospective, first-line, PULSE and POSIBA trials

Abstract

Metastatic colorectal cancer (mCRC) remains the third leading cause of cancer-related deaths worldwide. Wild-type (WT) K-RAS status is a major determinant for the efficacy of anti-EGFR therapy; however, as many as 40-60% patients (pts) even with this genetic background do not benefit from these regimens. While circulating cell-free miRNAs (cf-miRNAs) have emerged as an important class of cancer biomarkers, reent data suggests that miRNAs within the tumor-derived exosomal cargo (exo-miRNAs) might offer higher cancer specificity.